Artiva Biotherapeutics, Inc. Increase (Decrease) in Accounts Payable
Artiva Biotherapeutics, Inc. (ARTV) reported Increase (Decrease) in Accounts Payable of $1.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$780.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.81M, a 4319.51% increase year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$150.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$442.00K, a 162.78% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$760.00K, a 246.44% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $519.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$408.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.03M 10-Q · filed 2026-08-06 | $882.00K derived: sum of 3 quarters · filed 2026-08-06 | $440.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.81M 10-Q · filed 2026-05-08 | $1.66M derived: sum of 2 quarters · filed 2026-05-08 | $1.22M derived: sum of 3 quarters · filed 2026-05-08 | $1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$592.00K derived: sum of 2 quarters · filed 2026-03-10 | -$801.00K derived: sum of 3 quarters · filed 2026-08-06 | -$760.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$442.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$651.00K derived: sum of 2 quarters · filed 2026-08-06 | -$610.00K 10-Q · filed 2025-11-12 | -$692.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$168.00K 10-Q · filed 2026-08-06 | -$250.00K derived: sum of 3 quarters · filed 2026-08-06 | $454.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $41.00K 10-Q · filed 2026-05-08 | -$41.00K derived: sum of 2 quarters · filed 2026-05-08 | $663.00K derived: sum of 3 quarters · filed 2026-05-08 | -$291.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $622.00K derived: sum of 2 quarters · filed 2026-03-10 | -$332.00K derived: sum of 3 quarters · filed 2026-03-10 | $519.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $704.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$250.00K derived: sum of 2 quarters · filed 2025-11-12 | $601.00K 10-Q · filed 2025-11-12 | -$1.32M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$103.00K 10-Q · filed 2025-08-06 | -$2.02M derived: sum of 3 quarters · filed 2025-08-06 | -$439.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $851.00K 10-Q · filed 2025-05-08 | -$1.07M derived: sum of 2 quarters · filed 2025-05-08 | $515.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$336.00K derived: sum of 2 quarters · filed 2025-03-24 | -$408.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.51M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$72.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |